- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Standard of Care Durvalumab for Limited-Stage SCLC
Panelists discuss how the ADRIATIC trial investigating durvalumab in limited-stage small cell lung cancer (SCLC) has shown promising results, potentially addressing unmet needs in this patient population, and consider its potential impact on treatment algorithms and its possible emergence as a new standard of care if approved for this indication.
EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC
EP: 2.Established Multidisciplinary Therapies for SCLC
EP: 3.Immunotherapies for Extensive-Stage SCLC
EP: 4.Introducing Bispecifics for Extensive-Stage SCLC
EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC
EP: 6.Additional Immunotherapies on the Horizon for LS-SCLC
EP: 7.Payer and Patient Education Considerations for SCLC
EP: 8.Biomarker Discovery and Exploration for SCLC
EP: 9.Key Takeaways on Recent Advances in SCLC
EP: 10.Therapies Beyond the Front Line for SCLC
EP: 11.Timing and Urgency Considerations in SCLC
Now that we’ve discussed extensive-stage small cell lung cancer (SCLC), let’s move into limited stage. Durvalumab has also demonstrated encouraging results in patients with limited-stage SCLC in the ADRIATIC trial. Can you discuss the trial design and the key results that were seen?
How do you see durvalumab fitting into treatment algorithms if approved? Do you see it as a potential new standard of care for patients with limited-stage SCLC?
What are the unmet needs that the ADRIATIC trial addresses for patients with limited-stage SCLC?
